Proteomics International Laboratories Ltd - ESG Rating & Company Profile powered by AI
The analysis of Proteomics International Laboratories Ltd uses data points from across the web as well as from public documents by Proteomics International Laboratories Ltd. The SDG rating for Proteomics International Laboratories Ltd represents the company's reporting of the UN Sustainable Development Goals. This page includes a questions and answers section about Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 8.0; made up of an environmental score of 8.0, social score of 8.0 and governance score of 8.0.
8.0
High ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Proteomics International Laboratories Ltd | 8.0 | High |
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Proteomics International Laboratories Ltd have an accelerator or VC vehicle to help deliver innovation?
Does Proteomics International Laboratories Ltd disclose current and historical energy intensity?
Does Proteomics International Laboratories Ltd report the average age of the workforce?
Does Proteomics International Laboratories Ltd reference operational or capital allocation in relation to climate change?
Does Proteomics International Laboratories Ltd disclose its ethnicity pay gap?
Does Proteomics International Laboratories Ltd disclose cybersecurity risks?
Does Proteomics International Laboratories Ltd offer flexible work?
Does Proteomics International Laboratories Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Proteomics International Laboratories Ltd disclose the number of employees in R&D functions?
Does Proteomics International Laboratories Ltd conduct supply chain audits?
Does Proteomics International Laboratories Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Proteomics International Laboratories Ltd conduct 360 degree staff reviews?
Does Proteomics International Laboratories Ltd disclose the individual responsible for D&I?
Does Proteomics International Laboratories Ltd disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Proteomics International Laboratories Ltd disclose current and / or historical scope 2 emissions?
Does Proteomics International Laboratories Ltd disclose water use targets?
Does Proteomics International Laboratories Ltd have careers partnerships with academic institutions?
Did Proteomics International Laboratories Ltd have a product recall in the last two years?
Does Proteomics International Laboratories Ltd disclose incidents of discrimination?
Does Proteomics International Laboratories Ltd allow for Work Councils/Collective Agreements to be formed?
Has Proteomics International Laboratories Ltd issued a profit warning in the past 24 months?
Does Proteomics International Laboratories Ltd disclose parental leave metrics?
Does Proteomics International Laboratories Ltd disclose climate scenario or pathway analysis?
Does Proteomics International Laboratories Ltd disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Proteomics International Laboratories Ltd disclose the pay ratio of women to men?
Does Proteomics International Laboratories Ltd support suppliers with sustainability related research and development?
Does Proteomics International Laboratories Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Proteomics International Laboratories Ltd reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Proteomics International Laboratories Ltd involved in embryonic stem cell research?
Does Proteomics International Laboratories Ltd disclose GHG and Air Emissions intensity?
Does Proteomics International Laboratories Ltd disclose its waste policy?
Does Proteomics International Laboratories Ltd report according to TCFD requirements?
Does Proteomics International Laboratories Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Proteomics International Laboratories Ltd disclose energy use targets?
Does Proteomics International Laboratories Ltd disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Proteomics International Laboratories Ltd have a policy relating to cyber security?
Have a different question?
Potential Risks for Proteomics International Laboratories Ltd
These potential risks are based on the size, segment and geographies of the company.
Proteomics International Laboratories Limited operates as a medical technology company with a focus on the area of proteomics. It provides PromarkerD, a predictive test for diabetic kidney disease; and develops diagnostic tests for endometriosis and giardia. The company also offers analytical services, including specialist contract research, analytical, and consultancy. Proteomics International Laboratories Ltd has a research agreement with the Busselton Population Medical Research Institute to enhance diagnosis and treatment of lung conditions, such as asthma and chronic obstructive pulmonary disease; the Janssen Research & Development, LLC for the research of diabetic kidney and heart disease treatment; and partnership with QIMR Berghofer Medical Research Institute for the detection of oesophageal adenocarcinoma, the primary common form of oesophageal cancer in Australia. The company was founded in 2001 and is based in Perth, Australia.